Matrix metalloproteinases during and outside of migraine attacks without aura

To test the hypothesis that permeability of the blood–brain barrier (BBB) is altered during migraine attack due to enhanced activation of matrix metalloproteinases (MMPs), we investigated MMP-3, MMP-9 and tissue inhibitor of metalloproteases (TIMP)-1 in the external jugular vein during and outside of migraine attacks in 21 patients with migraine without aura. In addition, we measured plasma levels of several other proteins including MMP-7, -8, -10 and TIMP-2. We used Rules-Based Medicine multi-analyte profiling and protein array technologies to study plasma concentration of MMPs. There was no difference in MMP-9 and TIMP-1 levels between ictal and interictal periods. We found significantly decreased plasma levels of MMP-3 in the external jugular (P = 0.002) and cubital (P = 0.008) vein during attacks compared with outside of attacks. We found no correlation of ictal or interictal MMP-3, MMP-9 and TIMP-1 to migraine duration and frequency analysed in 21 patients (P > 0.05). There was no difference between ictal and interictal plasma levels of MMP-7, -8, -10 and TIMP-2 (P > 0.05). Our data suggest that plasma MMP-9 cannot be used as a biomarker of BBB disruption in migraine without aura. Decreased MMP-3 levels are an interesting and unexpected finding warranting further investigation.

[1]  O. Sakowitz,et al.  Spreading depolarizations occur in human ischemic stroke with high incidence , 2008, Annals of neurology.

[2]  K. Nakashima,et al.  Increased Plasma Matrix Metalloproteinase‐9 Levels in Migraineurs , 2007, Headache.

[3]  V. Yong,et al.  Targeting MMPs in acute and chronic neurological conditions , 2007, Neurotherapeutics.

[4]  D. Ethell,et al.  Matrix metalloproteinases in brain development and remodeling: Synaptic functions and targets , 2007, Journal of neuroscience research.

[5]  T. Sobrino,et al.  MMP‐9 Immunoreactivity in Acute Migraine , 2007, Headache.

[6]  J. Koziol,et al.  Microglial Activation and Matrix Protease Generation During Focal Cerebral Ischemia , 2007, Stroke.

[7]  G. Rosenberg,et al.  Blood–brain barrier disruption by stromelysin-1 facilitates neutrophil infiltration in neuroinflammation , 2006, Neurobiology of Disease.

[8]  M. Moskowitz,et al.  New insights into migraine pathophysiology , 2006, Current opinion in neurology.

[9]  A. Hamsten,et al.  Lower serum concentration of matrix metalloproteinase‐3 in the acute stage of myocardial infarction , 2006, Journal of internal medicine.

[10]  M. Mori,et al.  Serum matrix metalloproteinase-3 levels correlate with disease activity in relapsing-remitting multiple sclerosis , 2006, Journal of Neurology, Neurosurgery & Psychiatry.

[11]  R. Egleton,et al.  Chronic inflammatory pain leads to increased blood-brain barrier permeability and tight junction protein alterations. , 2005, American journal of physiology. Heart and circulatory physiology.

[12]  T. Davis,et al.  The Blood-Brain Barrier/Neurovascular Unit in Health and Disease , 2005, Pharmacological Reviews.

[13]  A. Quintana,et al.  Metallothionein reduces central nervous system inflammation, neurodegeneration, and cell death following kainic acid‐induced epileptic seizures , 2005, Journal of neuroscience research.

[14]  LT Perlee,et al.  Development and standardization of multiplexed antibody microarrays for use in quantitative proteomics , 2004, Proteome Science.

[15]  Hongwei Jin,et al.  Cortical spreading depression activates and upregulates MMP-9. , 2004, The Journal of clinical investigation.

[16]  R. Egleton,et al.  Blood-brain barrier tight junctions are altered during a 72-h exposure to lambda-carrageenan-induced inflammatory pain. , 2002, American journal of physiology. Heart and circulatory physiology.

[17]  J. Hidalgo,et al.  RETRACTED: M-CSF Deficiency Leads to Reduced Metallothioneins I and II Expression and Increased Tissue Damage in the Brain Stem after 6-Aminonicotinamide Treatment , 2002, Experimental Neurology.

[18]  Andrew K. Dunn,et al.  Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model , 2002, Nature Medicine.

[19]  V. Wee Yong,et al.  Metalloproteinases in biology and pathology of the nervous system , 2001, Nature Reviews Neuroscience.

[20]  R. Egleton,et al.  Inflammatory pain alters blood-brain barrier permeability and tight junctional protein expression. , 2001, American journal of physiology. Heart and circulatory physiology.

[21]  S. Kingsmore,et al.  Immunoassays with rolling circle DNA amplification: a versatile platform for ultrasensitive antigen detection. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[22]  J. Hidalgo,et al.  IL-6 Deficiency Leads to Reduced Metallothionein-I+II Expression and Increased Oxidative Stress in the Brain Stem after 6-Aminonicotinamide Treatment , 2000, Experimental Neurology.

[23]  C. Catania,et al.  Neurons and ECM regulate occludin localization in brain endothelial cells , 2000, Neuroreport.

[24]  N. Abbott.  Inflammatory Mediators and Modulation of Blood–Brain Barrier Permeability , 2000, Cellular and Molecular Neurobiology.

[25]  V. Yong.  The potential use of MMP inhibitors to treat CNS diseases. , 1999, Expert opinion on investigational drugs.

[26]  Joaquı́n Hernández,et al.  Impaired Inflammatory Response to Glial Cell Death in Genetically Metallothionein-I- and -II-Deficient Mice , 1999, Experimental Neurology.

[27]  U. Reuter,et al.  Migraine with Aura Shows Gadolinium Enhancement Which is Reversed Following Prophylactic Treatment , 1998, Cephalalgia : an international journal of headache.

[28]  S. Shapiro,et al.  Matrix metalloproteinase degradation of extracellular matrix: biological consequences. , 1998, Current opinion in cell biology.

[29]  T. Tilling,et al.  Basement Membrane Proteins Influence Brain Capillary Endothelial Barrier Function In Vitro , 1998, Journal of neurochemistry.

[30]  F. Barone,et al.  Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase-9 reduces infarct size. , 1998, Stroke.

[31]  Voon Wee Yong,et al.  Matrix metalloproteinases and diseases of the CNS , 1998, Trends in Neurosciences.

[32]  B. Rosen,et al.  Perfusion‐weighted imaging defects during spontaneous migrainous aura , 1998, Annals of neurology.

[33]  R. Konkol,et al.  Familial Hemiplegic Migraine With Crossed Cerebellar Diaschisis and Unilateral Meningeal Enhancement , 1997, Headache.

[34]  M Filippi,et al.  Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with MS , 1996, Neurology.

[35]  M. Kornfeld,et al.  Bacterial collagenase disrupts extracellular matrix and opens blood-brain barrier in rat , 1993, Neuroscience Letters.

[36]  M. Moskowitz.  Neurogenic inflammation in the pathophysiology and treatment of migraine , 1993, Neurology.

[37]  J. Enghild,et al.  Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9. , 1992, The Journal of biological chemistry.

[38]  M. Lauritzen,et al.  Regional cerebral blood flow during cortical spreading depression in rat brain: increased reactive hyperperfusion in low‐flow states , 1987, Acta neurologica Scandinavica.

[39]  Martin Lauritzen,et al.  Changes in regional cerebral blood flow during the course of classic migraine attacks , 1983, Annals of neurology.

[40]  J. Olesen,et al.  Focal hyperemia followed by spreading oligemia and impaired activation of rcbf in classic migraine , 1981, Annals of neurology.

[41]  A. A. Leão,et al.  SPREADING DEPRESSION OF ACTIVITY IN THE CEREBRAL CORTEX , 1944 .

[42]  P. Goadsby,et al.  Migraine Pathophysiology , 2005, Headache.

[43]  O. Kempski.  Cerebral edema. , 2001, Seminars in nephrology.

[44]  [Classification and diagnostic criteria for headache, cranial neuralgias and facial pain]. , 1993, Neurologia i neurochirurgia polska.

[45]  M. Lauritzen,et al.  Cerebral blood flow in migraine and cortical spreading depression. , 1987, Acta neurologica Scandinavica. Supplementum.